Matritech Promotes Bladder Cancer Awareness November 12-18 and Encourages People at Risk for the Cancer to be Tested.

NEWTON, Mass. -- Matritech, Inc. (Amex: MZT) a leading developer of protein-based diagnostic products for the early detection of cancer has joined forces for the second consecutive year with leading urologists, urology nurses, community based healthcare providers, bladder cancer patient advocates, and firefighters to raise awareness of bladder cancer during National Bladder Health Awareness Week, November 12-18, 2006, and urges people who are at risk for bladder cancer to ask their doctor to be tested for the cancer.

Matritech is providing a patient education kit "Bladder Cancer Awareness - Early Detection Saves Lives" with information and materials for physicians and advocates to help them educate the public about bladder cancer risk factors and early detection. The patient education materials can be accessed on the company's website at www.matritech.com.

Bladder cancer is curable when found early, but few recognize the symptoms early enough to seek testing. Unfortunately, one in four bladder cancers is diagnosed when it is already advanced, reducing the chances of survival and requiring expensive treatment.

"We are pleased to be able to provide physicians and patient advocates with educational materials to help them bring attention to a disease that is often overlooked in cancer awareness programs," said Stephen D. Chubb, Chairman and CEO of Matritech. "Bladder cancer is a serious malignancy and has the highest recurrence rate of any cancer. Our common goal is to reach the people at risk for bladder cancer and make them aware that as with all cancers - early detection helps save lives."

Matritech's NMP22[R] BladderChek([R]) Test, a point-of-care urine test, which has been reported to be cost effective for screening high risk groups because of its low cost and high accuracy, is being used in a number of states in local wellness programs that began providing testing for bladder cancer. Communities in Colorado, Wisconsin, Texas, California and Rhode Island recently completed screening programs for people at risk for bladder cancer.

In Rhode Island, a voluntary screening program for firefighters in five communities was sponsored by their local State Representatives and endorsed by the area fire chiefs and the Rhode Island Cancer Council. Legislation to make bladder cancer testing available annually to all firefighters in the state is also being sponsored by these state representatives. Other screening programs for firefighters are anticipated in California, Massachusetts, Florida, and Arizona. Firefighters have an increased risk of bladder cancer death.

Recommendations supporting the screening of high risk groups for bladder cancer with the NMP22[R] BladderChek([R]) Test were reported in the September 1, 2006 American Cancer Society's (ACS) journal Cancer. Screening for bladder cancer in high risk individuals with the NMP22[R] BladderChek([R]) Test could save lives and reduce overall medical expenses. All other cancer screening programs save lives but increase expenses.

According to the National Cancer Institute (NCI), the prevalence of bladder cancer in the U.S. has surpassed that of lung cancer. This cancer is linked to smoking and occupational exposure to chemicals, yet if detected early, bladder cancer is very treatable. The risk of bladder cancer may exponentially increase when a person who smokes is also exposed to carcinogens at the workplace.

One of the first signs of bladder cancer is blood in the urine (hematuria). Sometimes the urine appears normal and blood is detected only through a test. Other signs can include painful urination, increased frequency of urination, a feeling of needing to urinate but not being able to do so, and chronic bladder inflammation from recurrent urinary tract infections. While each of these symptoms might have benign causes, the possibility of bladder cancer should not be excluded.

Matritech also continues to stress the importance of testing women for bladder cancer. The Company believes women should be viewed as an at risk group when considering testing for bladder cancer. Historically women have been underestimated for bladder cancer risk; as a result, bladder cancer has been detected in women at later stages in the disease. Diagnosis in women is often delayed because symptoms are overlooked or misinterpreted. The percentage of men who survive ten years is greater than women who survive five. The Company also points to the recent SEER (Surveillance, Epidemiology and End Results) data from the National Cancer Institute, which indicates the prevalence of bladder cancer in women is similar to ovarian and cervical cancer. Bladder cancer has a higher mortality than cervical cancer.

In the absence of screening, one in four bladder cancers is detected when it is already advanced, requiring expensive treatment and has reduced survival. Screening high risk groups offers the potential for detecting cancers earlier, resulting in less extensive and less costly treatments, as well as improved survival. The five year survival rate is 94% for patients diagnosed with early stage, or noninvasive cancer, while patients with metastatic or advanced stages of the disease have as low as a 6% chance of surviving five years.

The cost from diagnosis to death for bladder cancer is higher than any other cancer. In the U.S., it's estimated that bladder cancer diagnosis and treatment generates $4 billion in direct costs. The cost of treating a bladder cancer when it is detected early is much less than treatment after a tumor has become advanced.

The patient education materials are also available on the UroToday website at www.urotoday.com.

About Bladder Cancer

There will be more than 63,000 new cases of bladder cancer in the U.S. this year and it is the 5th most common cancer among men and women. Bladder cancer is the second most common urologic malignancy in the U.S. after prostate cancer. It is almost as common in men as colon cancer. The prevalence of bladder cancer in the U.S. is higher than lung cancer and its prevalence in women is similar to ovarian cancer. It is more common and has a higher mortality than cervical cancer. Bladder cancer has the highest rate of recurrence with a 50 to 85 percent recurrence within six to 12 months. Currently there are more than 500,000 Americans with a history of bladder cancer. The most common risk factor for bladder cancer is smoking. Occupational exposures to chemicals (aromatic amines) used in dry cleaning facilities and the production of dyes, paper, rope, apparel, rubber and petroleum products have been associated with increased risk for bladder cancer. Other industrial exposures implicated as risk factors for developing bladder cancer include combustion gases and soot from coal, chlorinated aliphatic hydrocarbons, and chlorination by-products in heated water.

About Matritech

Matritech is using its patented proteomics technology to develop diagnostics for the detection of a variety of cancers. The Company's first two products, the NMP22[R]Test Kit and NMP22[R] BladderChek([R]) Test, have been FDA approved for the monitoring and diagnosis of bladder cancer. The NMP22 BladderChek Test is based on Matritech's proprietary nuclear matrix protein (NMP) technology, which correlates levels of NMPs in body fluids to the presence of cancer. Beginning with a patent portfolio licensed exclusively from the Massachusetts Institute of Technology (MIT), Matritech's patent portfolio has grown to 14 other U.S. patents. In addition to the NMP22 protein marker utilized in the NMP22 Test Kit and NMP22 BladderChek Test, the Company has discovered other proteins associated with cervical, breast, prostate, and colon cancer. The Company's goal is to utilize protein markers to develop, through its own research staff and through strategic alliances, clinical applications to detect cancer. More information about Matritech is available at www.matritech.com.

Statement under the Private Securities Litigation Reform Act 

Any forward-looking statements in this press release including those related to the Company's expectations regarding future sales of and markets for the Company's products, and business prospects are subject to a number of risks and uncertainties, many of which are beyond the Company's control. Please refer to the risk factors detailed in the Company's periodic reports and registration statements as filed with the Securities and Exchange Commission. These forward-looking statements are neither promises nor guarantees. There can be no assurance that the Company's expectations for its products or future financial performance will be achieved. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Matritech undertakes no responsibility to revise or update any such forward-looking information.